Presentation is loading. Please wait.

Presentation is loading. Please wait.

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2012 Summary Slides SUM12_1.ppt.

Similar presentations


Presentation on theme: "Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2012 Summary Slides SUM12_1.ppt."— Presentation transcript:

1 Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2012 Summary Slides SUM12_1.ppt

2 Location of Centers Participating in the CIBMTR 2012 SUM12_22.ppt Slide 2

3 Transplants SUM12_23.ppt Slide 3 Transplant Activity in the U.S

4 SUM12_24.ppt Allogeneic Stem Cell Sources by Recipient Age Age 20 yrsAge 20 yrs Slide 4 Transplants, %

5 SUM12_25.ppt Autologous Stem Cell Sources by Recipient Age, Age 20 yrsAge 20 yrs Slide 5 Transplants, %

6 SUM12_26.ppt Trends in Transplants by Type and Recipient Age* * Transplants for AML, ALL, NHL, Hodgkin Disease, Multiple Myeloma Slide 6 Transplants, % Allogeneic TransplantsAutologous Transplants

7 SUM12_27.ppt Trends in Transplants by Transplant Type and Recipient Age* * Transplants for AML, ALL, NHL, Hodgkin Disease, Multiple Myeloma Slide 7 Transplants, % Allogeneic TransplantsAutologous Transplants

8 Indications for Hematopoietic Stem Cell Transplants in the United States, 2010 (Inflation factor: Auto=1.25 (80%), Allo=1.05 (95%), All Transplants) SUM12_28.ppt Slide 8 Number of Transplants

9 Indications for Hematopoietic Stem Cell Transplants for Age 20yrs, in the U.S., 2010 (Inflation factor: Auto=1.25 (80%), Allo=1.05 (95%), All Transplants) SUM12_29.ppt Slide 9 Number of Transplants

10 SUM12_30.ppt Allogeneic Transplants for Age 20yrs, Registered with the CIBMTR, by Donor Type and Graft Source - Slide 10 Number of Transplants

11 Allogeneic Transplants for Age 20yrs, Registered with the CIBMTR, by Donor Type and Graft Source - Slide 11 Number of Transplants SUM12_31.ppt

12 Unrelated Donor Stem Cell Sources by Recipient Age Age 20 yrsAge 20 yrs Slide 12 Transplants, % SUM12_32.ppt

13 Unrelated Cord Blood Transplants by Age Registered with the CIBMTR Slide 13 Number of Transplants * * Data incomplete SUM12_33.ppt

14 One-Year Survival, % Slide 14 One-year Survival by Year of Transplant, Donor and Age, Worldwide, In any remission, Acute Leukemia, CML or MDS- SUM12_34.ppt

15 100-day Mortality after Autologous Transplants, 2010 Slide 15 Mortality, % SUM12_35.ppt

16 100-day Mortality after HLA-identical Sibling Transplants, 2010 Slide 16 Early Disease Intermediate Disease Advanced Disease Chronic Phase Accelerated Phase Blast Phase Other Mortality, % SUM12_36.ppt

17 100-day Mortality after Unrelated Donor Transplants, Slide 17 Early Disease Intermediate Disease Advanced Disease Chronic Phase Accelerated Phase Blast Phase Other Mortality, % SUM12_37.ppt

18 Causes of Death after Transplants Done in Autologous Infection (7%) Other (17%) Organ Failure (3%) New Malignancy (1%) Primary Disease (72%) Unrelated Donor Infection (18%) Other (18%) Organ Failure (8%) Primary Disease (37%) New Malignancy (1%) GVHD (18%) Slide 18 HLA-identical Sibling Infection (13%) Other (16%) Primary Disease (49%) GVHD (16%) Organ Failure (5%) New Malignancy (1%) SUM12_38.ppt

19 Allogeneic Transplants Registered with the CIBMTR, by Conditioning Regimen Intensity & Age - * * Data incomplete Slide 19 Number of Transplants SUM12_39.ppt

20 Allogeneic Transplants after Reduced- intensity Conditioning, by Donor Type, Registered with CIBMTR Slide 20 Number of Transplants SUM12_40.ppt

21 One-Year Survival, % Slide 21 Percentage of Reduced Intensity Conditioning Allo-HCTs, Registered with CIBMTR, by Year of Transplant & Disease - SUM12_41.ppt

22 Indications for Hematopoietic Stem Cell Transplants for Age 50yrs, in the U.S., 2010 SUM12_42.ppt Slide 22 Number of Transplants

23 Allogeneic Transplants in the U.S., Registered with the CIBMTR, by Donor Type - Slide 23 Transplants, % SUM12_43.ppt

24 SUM12_44.ppt Hematopoietic Cell Transplant Comorbid Index of U.S. Transplant Recipients by Group Age Slide 24 Transplants, %

25 Probability of Survival after HLA-identical Sibling Donor Transplants for AML, By Disease Status - Years Early (N=7,210) Intermediate (N=1,906) Advanced (N=2,923) Probability of Survival, % SUM12_2.ppt Slide 25 P <

26 Probability of Survival after Unrelated Donor Transplants for AML, By Disease Status - Years Early (N=5,364) Intermediate (N=3,374) Advanced (N=3.702) Probability of Survival, % SUM12_3.ppt Slide 26 P <

27 Survival after HLA-identical Sibling Donor Transplants for AML, Age 20 yrs, by Disease Status - Years Early (N=1,292) Intermediate (N=268) Advanced (N=270) Probability of Survival, % SUM12_4.ppt Slide 27 P <

28 Probability of Survival after Autologous Transplants for AML, by Disease Status - Years Early (N=2,139) Intermediate (N=735) Advanced (N=152) Probability of Survival, % SUM12_5.ppt Slide 28 P <

29 Probability of Survival after Allogeneic Transplants for MDS, by Disease Status and Donor Type - SUM12_6.ppt Slide 29 Years Probability of Survival, % Early, sibling donor (N=750) Early, unrelated donor (N=890) Advanced, sibling donor (N=1,407) Advanced, unrelated donor (N=1,660) P <

30 Survival after HLA-identical Sibling Donor Transplants for ALL, Age 20 yrs, by Disease Status - SUM12_7.ppt Slide 30 Years Probability of Survival, % P < Early (N=849) Intermediate (N=1,203) Advanced (N=210)

31 Probability of Survival after Unrelated Donor Transplants for ALL, Age 20 yrs, By Disease Status - SUM12_8.ppt Slide 31 Years Probability of Survival, % P < Intermediate (N=2,034) Advanced (N=289) Early (N=977)

32 Survival after HLA-identical Sibling Donor Transplants for ALL, Age 20 yrs, By Disease Status - Slide 32 Years Probability of Survival, % P < Intermediate (N=715) Advanced (N=584) Early (N=2,214) SUM12_9.ppt

33 Probability of Survival after Unrelated Donor Transplants for ALL, Age 20 yrs, By Disease Status - Slide 33 Years Probability of Survival, % P < Intermediate (N=1,075) Advanced (N=767) Early (N=1,818) SUM12_10.ppt

34 Probability of Survival after HLA-identical Sibling Donor Transplants for CML, By Disease Status and Transplant Year - Slide 34 Years Probability of Survival, % P < CP, (N=2,239) AP, (N=291) CP, (N=2,498) AP, (N=360) SUM12_11.ppt

35 Survival after Autologous and HLA-matched Sibling Donor Hematopoietic Cell Transplants for CLL, by Donor Type and Conditioning Regimen Intensity - Slide 35 Years Probability of Survival, % P < Autologous transplant (N=270) Myeloablative conditioning (N=450) Reduced-intensity conditioning (N=871) SUM12_12.ppt

36 Probability of Survival after Allogeneic Transplants for SAA, By Donor Type and Age - Slide 36 Years Probability of Survival, % P < y, Sibling Donor (N=1,375) 20y, Sibling Donor (N=1,425) 20y, Unrelated Donor (N=654) 20y, Unrelated Donor (N=634) SUM12_13.ppt

37 Probability of Survival after Autologous Transplants for Hodgkin Disease, By Disease Status - Slide 37 Years Probability of Survival, % P < CR (N=2,907) Not in CR, sensitive (N=3,832) Not in CR, resistant (N=1,237) SUM12_14.ppt

38 Probability of Survival after Allogeneic Transplants for Hodgkin Disease, By Conditioning Regimen and Donor Type - Slide 38 Years Probability of Survival, % P = Sibling Donor (N=356) Unrelated Donor (N=205) SUM12_15.ppt

39 Survival after Autologous Transplants for Follicular Lymphoma, By Disease Status - Slide 39 Years Probability of Survival, % P < Sensitive (N=2,676) Resistant (N=279) SUM12_16.ppt

40 Probability of Survival after Allogeneic and HLA-identical Sibling Transplants for Follicular Lymphoma, By Disease Status - Slide 40 Years Probability of Survival, % P = Sensitive (N=840) Resistant (N=212) SUM12_17.ppt

41 Probability of Survival after Autologous Transplants for Diffuse Large B-Cell Lymphoma, By Disease Status - Slide 41 Years Probability of Survival, % P < Sensitive (N=8,891) Resistant (N=1,033) SUM12_18.ppt

42 Probability of Survival after HLA-identical Sibling Transplants for Diffuse Large B-Cell Lymphoma, By Disease Status - Slide 42 Years Probability of Survival, % P < Sensitive (N=503) Resistant (N=219) SUM12_19.ppt

43 Probability of Survival after Transplants for Mantle Cell Lymphoma, By Donor Type - Slide 43 Years Probability of Survival, % P < Sibling donor (N=554) Unrelated donor (N=389) Autologous (3,173) SUM12_20.ppt

44 Probability of Survival after Transplants for Multiple Myeloma, By Donor Type - Slide 44 Years Probability of Survival, % P < Sibling Donor (N=892) Unrelated donor (N=380) Autologous (N27,979) SUM12_21.ppt


Download ppt "Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2012 Summary Slides SUM12_1.ppt."

Similar presentations


Ads by Google